New hope for kids with relapsed cancers: experimental combo enters human testing
NCT ID NCT04308330
First seen Apr 23, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This early-phase study tests a four-drug combination (vorinostat, vincristine, irinotecan, and temozolomide) in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goals are to find a safe dose and understand side effects. About 30 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical College
RECRUITINGValhalla, New York, 10595, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.